AtlasXomics
$6.2Mtotal raised · 8 rounds on record
$3.9Mlatest round · Venture round · Dec 2021 · 4 yr ago
$3.1Mgrants · 5 grants · CORDIS
10+team · employees, estimated range
Overview
Boost your research with our spatial epigenetic assays. Our innovative kit offers spatial-ATAC-seq and CUT & Tag tools, allowing you to identify chromatin accessibility differences in various tissues.
Funding and backers
Total raised
$6.2M
8 rounds on record
Latest round
$3.9M
Venture round · Dec 2021 · 4 yr ago
Team
11-50
employees, estimated range
Grants
$3.1M
5 grants · CORDIS
The money's age
Long since its last round
58 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 1, 2024
Won a grant $400k · CORDIS
Mar 11, 2024
Won a grant $400k · CORDIS
Jan 23, 2024
Partnership AtlasXomics and EpiCypher announce partnership to commercialize spatial epigenomics assays · PRNewswire
Sep 19, 2023
Won a grant $1.8M · CORDIS
Sep 16, 2022
Won a grant $251k · CORDIS
May 1, 2022
Won a grant $222k · CORDIS
Dec 22, 2021
Raised a round Venture round $3.9M · SEC Form D
Mar 9, 2021
Board appointment John Steffens, Director · SEC Form D
Feb 26, 2021
Raised a round Venture round $1.8M · SEC Form D
May 19, 2020
Raised a round Convertible Note $470k · SEC Form D
2020
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Jul 2024 | $400k | — | CORDIS |
| Grant | Mar 2024 | $400k | — | CORDIS |
| Grant | Sep 2023 | $1.8M | — | CORDIS |
| Grant | Sep 2022 | $251k | — | CORDIS |
| Grant | May 2022 | $222k | — | CORDIS |
| Venture round | Dec 2021 | $3.9M | — | SEC Form D |
| Venture round | Feb 2021 | $1.8M | — | SEC Form D |
| Convertible Note | May 2020 | $470k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | AtlasXomics Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Kenneth WangExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
As your research partner, EpiCypher provides cutting-edge tools and services for epigenetics and chromatin biology research.
Next Generation Spatial Biology: AmberGen’s patented Miralys™ Photocleavable Mass-Tag Imaging Significantly Boosts the Capability of Mass…
Geolava builds spatial intelligence systems powered by world models, translating spatial physics into financial advantage and exposure.
Pioneering new therapies for diseases of chromatin dysfunction. There is a necessity for new types of treatments in diseases like Pediatric…
Spaceframe is a spatial computing app for web research, notetaking, moodboarding, and writing with .
Alpenglow Biosciences provides the Aurora 3D spatial biology platform, including the 3Di HOTLS microscope, 3D histology services…
Financials
Total raised
$9.3M
Latest round
Grant
Funding rounds
8
People
Kenneth Wang
Executive Officer, Director
Gregory Ho
Director
Richard Andersson
Director
John Steffens
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
AtlasXomics and EpiCypher announce partnership to commercialize spatial epigenomics assays
/PRNewswire/ -- AtlasXomics and EpiCypher announce their partnership to develop CUT&Tag kits and assay services for spatial epigenomics applications. These...
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
New Haven
United States
HQ
10-50 est. staff